Company intelligence / Profile preview

LexaGene

Beverly, Massachusetts, United Stateslexagenelifesciences.com ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

LexaGene developed the MiQLab System—an automated genetic analyzer for rapid pathogen detection with applications in veterinary diagnostics, human clinical diagnostics, food/water safety testing. The system was commercialized but the company filed for Chapter 7 bankruptcy in February 2023. Its assets were acquired by Meridian LGH Holdings and subsequently transferred to a new entity ("LexaGene Life Sciences") formed to further develop and commercialize the technology. No current clinical trial results as it is a diagnostic device.

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceDiagnostic platform
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on LexaGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LexaGene.

Explore the full profile